Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8023425 | 0.88 | TSHR (0.30) | ALDH1A1CA1CA2CA7PIK3CD | |
| SCHEMBL14244877 | 0.83 | SOAT1 (0.32) | — | |
| SCHEMBL4913885 | 0.78 | CTSK (0.38) | DGAT1CA14SMN1; SMN2ALDH1A1CA12 | |
| SCHEMBL187785 | 0.77 | — | — | |
| SCHEMBL14769869 | 0.75 | ALDH1A1 (0.52) | ALDH1A1 | |
| SCHEMBL6923274 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL38665288 | 0.74 | DGAT1 (0.50) | DGAT1CA14SMN1; SMN2ALDH1A1CA12 | |
| SCHEMBL6729088 | 0.74 | TP53 (0.33) | ALDH1A1 | |
| SCHEMBL1107368 | 0.74 | GAA (0.44) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL6729083 | 0.74 | TSHR (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11762287-B2 | Onium salt compound, chemically amplified resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-09-19 | — | — | US | disclosed |
| US-9988394-B2 | Oxabicycloheptane prodrugs | LIXTE BIOTECHNOLOGY INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20160333024-A1 | OXABICYCLOHEPTANE PRODRUGS | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20080161394-A1 | Cosmetic composition comprising at least one volatile carbonic acid ester | L'OREAL S.A. (FR) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11762287-B2 | Onium salt compound, chemically amplified resist composition and patterning process | IDUA, SLC6A5, SLC6A9 | DGAT1 140/4885CA14 863/4885SMN1; SMN2 3745/4885 |
| US-20160333024-A1 | OXABICYCLOHEPTANE PRODRUGS | UGT2B7, UGT1A6, UGT1A1 | DGAT1 1315/4885CA14 1183/4885SMN1; SMN2 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.